Skip to main content

Advertisement

Table 2 Anatomic origin and microbiologic findings of S. maltophilia bacteremia in study participants

From: Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone–resistant strains

Factors Survivors N = 44 Non-survivors N = 82 p value
Infection source
 Pneumonia 12 (27.9) 23 (28.0) 0.987
 Catheter-related infection 15 (34.1) 34 (42.0) 0.202
 Intra-abdominal infection 16 (36.4) 22 (27.2) 0.285
 Soft tissue infection 0 (0.0) 5 (6.2) 0.161
 Urinary tract infection 1 (2.3) 0 (0.0) 0.352
 Polymicrobial infection 18 (40.9) 36 (43.9) 0.746
Antibiotics susceptibility
 Quinolone resistance 5 (11.6) 34 (41.5) 0.001
 TMP-SMX resistance 3 (6.8) 12 (14.6) 0.197
 Resistant straina 17 (38.6) 49 (59.8) 0.024
Treatment
 Empirical antibiotic use
  Cephalosporins 2 (4.5) 6 (7.4) 0.711
  Carbapenems 13 (29.5) 42 (51.9) 0.016
  Fluoroquinolones 13 (29.5) 8 (9.8) 0.004
  BLBLIs 14 (31.8) 16 (19.5) 0.122
  TMP-SMX 0 (0.0) 0 (0.0)
 Definitive antibiotic use
  Carbapenems 2 (4.5) 16 (19.5) 0.022
  Fluoroquinolones 21 (47.7) 19 (23.5) 0.005
  BLBLIs 3 (6.8) 5 (6.2) 1.000
  TMP-SMX 4 (9.1) 27 (33.3) 0.003
  Inappropriate antimicrobial therapyb, yes 14 (31.8) 25 (30.9) 0.912
  1. Note. BLBLIs Beta-lactam/beta-lactamase inhibitors, TMP-SMX Trimethoprim-sulfamethoxazole
  2. The data were expressed as number (%) or median (interquartile range)
  3. aResistant strain, Quinolone or/and TMP-SMX resistance
  4. bAppropriate antimicrobial therapy, the administration of at least one agent to which the index SM isolate was susceptible in vitro